DS
BMRN icon

DRW Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

DRW Securities’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,426
Closed -$702K – 1011
2026
Q1 		$702K Buy
12,426
+7,288
+142% +$425K 0.01% 461
2025
Q4 		$305K Buy
5,138
+158
+3% +$8.6K 0.01% 665
2025
Q3 		$270K Sell
4,980
-1,956
-28% -$112K ﹤0.01% 908
2025
Q2 		$381K Buy
+6,936
New +$408K 0.01% 620
2024
Q2 		– Sell
-7,400
Closed -$646K – 534
2024
Q1 		$646K Buy
+7,400
New +$662K 0.02% 210

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

DRW Securities's BMRN Position: Q2 2026 in Review

DRW Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 12,426 shares — an estimated $702K sold.

DRW Securities first reported a position in BMRN in Q1 2024 and held it in 5 quarters. The position peaked at $702K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • DRW Securities reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • DRW Securities sold 12,426 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $702K.
  • DRW Securities first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • DRW Securities's BioMarin Pharmaceuticals position peaked at $702K in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.